Concord Biotech Share Price

Concord Biotech Limited is an India-based research and development-driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. Its business verticals include active pharmaceutical ingredients (API), finished formulations, and contract development and manufacturing services. It manufactures API through fermentation and semi-synthetic processes and finished formulations. The Company’s offerings span both biopharmaceutical APIs and formulations across therapeutic areas like immunosuppressants, oncology, anti-infectives nephrology, and critical care. Its portfolio also includes fermentation-based APIs in antibacterial, antifungal, and other therapeutic segments. Its API products include Mycophenolate Mofetil, Sirolimus, Pimecrolimus, Voclosporin, Mupirocin, Mupirocin Calcium, Vancomycin Hydrochloride, and Teicoplanin. Its API products under development include Daptomycin, Idarubicin, and Pirarubicin.As of 13 Jun 2026, Concord Biotech share price is ₹1,353.80. The stock opened at ₹1,345.10, compared to its previous close of ₹1,343.30. During today's trading session, Concord Biotech share price moved in the range of ₹1,335.60 to ₹1,367.40, with an average price of ₹1,351.50 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,335.60 and a high of ₹1,367.40. On the performance front, Concord Biotech share price has declined by 1.17% over the last six months and is down 34.40% on a year-on-year basis.

The market capitalization of Concord Biotech is ₹14,074 Crs, with a P/E ratio of 54.3 and a dividend yield of 0.56%.